289 related articles for article (PubMed ID: 31393200)
1. Preventive drug therapy and contralateral breast cancer: summary of the evidence of clinical trials and observational studies.
Bens A; Langballe R; Bernstein JL; Cronin-Fenton D; Friis S; Mellemkjaer L
Acta Oncol; 2019 Nov; 58(11):1581-1593. PubMed ID: 31393200
[No Abstract] [Full Text] [Related]
2. Preventive therapy for breast cancer: a consensus statement.
Cuzick J; DeCensi A; Arun B; Brown PH; Castiglione M; Dunn B; Forbes JF; Glaus A; Howell A; von Minckwitz G; Vogel V; Zwierzina H
Lancet Oncol; 2011 May; 12(5):496-503. PubMed ID: 21441069
[TBL] [Abstract][Full Text] [Related]
3. Chemoprevention of hormone receptor-negative breast cancer: new approaches needed.
Uray IP; Brown PH
Recent Results Cancer Res; 2011; 188():147-62. PubMed ID: 21253797
[TBL] [Abstract][Full Text] [Related]
4. Breast cancer prevention by antihormones and other drugs: where do we stand?
Lazzeroni M; DeCensi A
Hematol Oncol Clin North Am; 2013 Aug; 27(4):657-72, vii. PubMed ID: 23915737
[TBL] [Abstract][Full Text] [Related]
5. Prevention of breast cancer: current state of the science and future opportunities.
Uray IP; Brown PH
Expert Opin Investig Drugs; 2006 Dec; 15(12):1583-600. PubMed ID: 17107283
[TBL] [Abstract][Full Text] [Related]
6. Estrogen receptor status of primary breast cancer is predictive of estrogen receptor status of contralateral breast cancer.
Swain SM; Wilson JW; Mamounas EP; Bryant J; Wickerham DL; Fisher B; Paik S; Wolmark N
J Natl Cancer Inst; 2004 Apr; 96(7):516-23. PubMed ID: 15069113
[TBL] [Abstract][Full Text] [Related]
7. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
[TBL] [Abstract][Full Text] [Related]
8. Association of Adjuvant Tamoxifen and Aromatase Inhibitor Therapy With Contralateral Breast Cancer Risk Among US Women With Breast Cancer in a General Community Setting.
Gierach GL; Curtis RE; Pfeiffer RM; Mullooly M; Ntowe EA; Hoover RN; Nyante SJ; Feigelson HS; Glass AG; Berrington de Gonzalez A
JAMA Oncol; 2017 Feb; 3(2):186-193. PubMed ID: 27711920
[TBL] [Abstract][Full Text] [Related]
9. The rationale and potential of cancer chemoprevention with special emphasis on breast cancer.
Puntoni M; Decensi A
Eur J Cancer; 2009 Sep; 45 Suppl 1():346-54. PubMed ID: 19775631
[No Abstract] [Full Text] [Related]
10. Anti-tumor effects of letrozole.
Miller WR; Anderson TJ; Dixon JM
Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
[TBL] [Abstract][Full Text] [Related]
11. Prevention of hormone-related cancers: breast cancer.
Dunn BK; Wickerham DL; Ford LG
J Clin Oncol; 2005 Jan; 23(2):357-67. PubMed ID: 15637398
[TBL] [Abstract][Full Text] [Related]
12. Endocrine therapy trials of aromatase inhibitors for breast cancer in the adjuvant and prevention settings.
Ingle JN
Clin Cancer Res; 2005 Jan; 11(2 Pt 2):900s-5s. PubMed ID: 15701884
[TBL] [Abstract][Full Text] [Related]
13. Tamoxifen and contralateral breast cancer.
O'Regan R; Jordan VC; Gradishar WJ
J Am Coll Surg; 1999 Jun; 188(6):678-83. PubMed ID: 10359362
[No Abstract] [Full Text] [Related]
14. The association between type of endocrine therapy and development of estrogen receptor-1 mutation(s) in patients with hormone-sensitive advanced breast cancer: A systematic review and meta-analysis of randomized and non-randomized trials.
Najim O; Seghers S; Sergoynne L; Van Gaver H; Papadimitriou K; Wouters K; Trinh XB; Huizing MT; Tjalma W
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188315. PubMed ID: 31647985
[TBL] [Abstract][Full Text] [Related]
15. Focus on anastrozole and breast cancer.
Mokbel K
Curr Med Res Opin; 2003; 19(8):683-8. PubMed ID: 14687437
[TBL] [Abstract][Full Text] [Related]
16. Chemoprevention of breast cancer.
Castrellon AB; Glück S
Expert Rev Anticancer Ther; 2008 Mar; 8(3):443-52. PubMed ID: 18366291
[TBL] [Abstract][Full Text] [Related]
17. Beyond aspirin-cancer prevention with statins, metformin and bisphosphonates.
Gronich N; Rennert G
Nat Rev Clin Oncol; 2013 Nov; 10(11):625-42. PubMed ID: 24080598
[TBL] [Abstract][Full Text] [Related]
18. Aromatase inhibitors in breast cancer: an overview.
Altundag K; Ibrahim NK
Oncologist; 2006 Jun; 11(6):553-62. PubMed ID: 16794235
[TBL] [Abstract][Full Text] [Related]
19. Tamoxifen resistant and refractory breast cancer: the value of aromatase inhibitors.
Goss PE; Strasser K
Drugs; 2002; 62(6):957-66. PubMed ID: 11929341
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of breast cancer in the older patient.
Minton SE
Hematol Oncol Clin North Am; 2000 Feb; 14(1):113-30. PubMed ID: 10680075
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
